INNOVACAP logo

Innova Captab Limited Stock Price

NSEI:INNOVACAP Community·₹55.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author

INNOVACAP Share Price Performance

₹0
-897.30 (-100.00%)
₹1,078.50
Fair Value
₹0
-897.30 (-100.00%)
Price ₹0

INNOVACAP Community Narratives

·
Fair Value ₹1.08k 10.3% undervalued intrinsic discount

New Jammu Facility Will Capture Global Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
₹1.08k
10.3% undervalued intrinsic discount
Revenue
21.29% p.a.
Profit Margin
11.45%
Future PE
27.29x
Price in 2029
₹1.59k

Trending Discussion

No trending discussion available.

Updated Narratives

INNOVACAP logo

INNOVACAP: Higher Fair Value And Governance Moves Will Support Bullish Re Rating

Fair Value: ₹1.08k 10.3% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

0 Risks
3 Rewards

Innova Captab Limited Key Details

₹16.3b

Revenue

₹10.7b

Cost of Revenue

₹5.6b

Gross Profit

₹4.2b

Other Expenses

₹1.4b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
24.63
34.60%
8.65%
31.4%
View Full Analysis

About INNOVACAP

Founded
2005
Employees
n/a
CEO
Vinay Lohariwala
WebsiteView website
innovacaptab.com

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors, stockists, and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Recent INNOVACAP News & Updates

Narrative Update Jun 26

INNOVACAP: Higher Fair Value And Governance Moves Will Support Bullish Re Rating

Analysts have revised their price target for Innova Captab to ₹1,078.50 from ₹891.50, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key inputs to the new valuation view. What’s in the News for Innova Captab The board has scheduled a meeting on May 25, 2026, to consider the reappointment of M/s.

Recent updates

No updates